WaveMan
WaveMan · Company
ENOV · Enovis Corp
> Search tickers & screens ⌘K
LIVE
← All companies

ENOV Enovis (ENOV) Insider Trading, Ownership & Congress Trades

Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001420800
Quote by TradingView
C-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
136
13F, latest reported quarter

What the filings say about ENOV

Insiders, 180 days
+$541.7K net bought
2 buyers

Enovis insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Enovis CORP insiders bought a net $541.7K of stock across 60 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
McDonald Damien
Chief Executive Officer
BUY
2026-09-04 SEC
13,035
$249.6K
+5.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 11, 2025.
  • The trade is 5.3% of the 247,077 shares held after it.
  • 1 other insider bought within 30 days.
  • 136 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer McDonald Damien bought about $249.6K of ENOV on Sep 4, 2026, the largest insider purchase at the company since 2025; 1 other insider bought within 30 days and 136 funds added in the latest 13F quarter.
Engert Oliver
Chief Administrative Officer
BUY
2026-09-08 SECtraded 2026-09-04
2,660
$50.0K
+11.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Sep 3, 2026.
  • -9.1% median (-7.0% mean) 90-day return after 11 previous buys.
  • The trade is 4.2% of the 63,898 shares held after it.
  • 1 other insider bought within 30 days.
  • 136 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Administrative Officer Engert Oliver bought about $50.0K of ENOV on Sep 4, 2026; 1 other insider bought within 30 days and 136 funds added in the latest 13F quarter.
Engert Oliver
Chief Administrative Officer
BUY
2026-09-04 SECtraded 2026-09-03
5,140
$100.0K
+5.9%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Sep 2, 2026.
  • -9.1% median (-7.0% mean) 90-day return after 11 previous buys.
  • The trade is 8.4% of the 61,238 shares held after it.
  • 1 other insider bought within 30 days.
  • 136 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Administrative Officer Engert Oliver bought about $100.0K of ENOV on Sep 3, 2026; 1 other insider bought within 30 days and 136 funds added in the latest 13F quarter.
Engert Oliver
Chief Administrative Officer
BUY
2026-09-04 SECtraded 2026-09-02
2,458
$49.9K
+5.9%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Jun 15, 2026.
  • -9.1% median (-7.0% mean) 90-day return after 11 previous buys.
  • The trade is 4.4% of the 56,098 shares held after it.
  • 1 other insider bought within 30 days.
  • 136 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Administrative Officer Engert Oliver bought about $49.9K of ENOV on Sep 2, 2026; 1 other insider bought within 30 days and 136 funds added in the latest 13F quarter.
Engert Oliver
Chief Administrative Officer
BUY
2026-06-16 SECtraded 2026-06-15
1,000
$20.9K
+1.5%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Jun 11, 2026.
  • -8.6% median (-6.4% mean) 90-day return after 10 previous buys.
  • The trade is 1.9% of the 53,640 shares held after it.
  • No other insider bought within 30 days.
  • 136 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Administrative Officer Engert Oliver bought about $20.9K of ENOV on Jun 15, 2026; 136 funds added in the latest 13F quarter.
60 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 55 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$541.7K over 180 days
+$449.6K over 90 days
more than 87% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
136 funds bought in last quarter
more than 71% of Medical Devices
Revenue
+6.7% year over year
below 60% of Medical Devices
Margin
-52.7% net margin
below 68% of Medical Devices
Buybacks
$3.5M repurchased, FY to 2025-12-31
below 78% of Medical Devices
Short interest
20.0% of the float short (float per yahoo 2026-10-26) · 5.8 days to cover · settled 2026-09-30
more than 98% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ENOV

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-35.0%12M
-46%-31%-15%+1%2025-102025-122026-022026-042026-062026-082026-10 2026-09-04 · McDonald Damien bought $249.6K2026-09-03 · Engert Oliver bought $100.0K2025-11-25 · KLECKNER JOHN bought $74.8K2026-09-04 · Engert Oliver bought $50.0K2026-09-02 · Engert Oliver bought $49.9K2026-02-27 · Engert Oliver bought $25.5K2026-03-03 · Engert Oliver bought $24.8K2026-03-10 · Engert Oliver bought $23.9K2026-03-13 · Engert Oliver bought $23.7K2026-03-09 · Engert Oliver bought $23.4K2026-06-10 · Engert Oliver bought $23.0K2026-06-01 · Engert Oliver bought $22.2K2026-06-11 · Engert Oliver bought $21.8K2026-06-15 · Engert Oliver bought $20.9K2025-12-09 · PRYOR DANIEL A sold $18.1K2026-03-06 · Engert Oliver bought $12.2K2025-12-09 · PRYOR DANIEL A sold $9.1K2025-12-09 · PRYOR DANIEL A sold $9.1K2025-12-09 · PRYOR DANIEL A sold $9.1K2026-03-04 · Engert Oliver bought $6.3K2026-03-06 · Engert Oliver bought $6.1K2026-06-11 · Engert Oliver bought $4.2K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ENOV: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
10,295,666 sh
$213.1M
AMERICAN CENTURY COMPANIES INC
6,106,561 sh
$126.4M
VANGUARD PORTFOLIO MANAGEMENT LLC
3,926,268 sh
$81.3M
Rubric Capital Management LP
3,900,000 sh
$80.7M
VANGUARD CAPITAL MANAGEMENT LLC
2,484,318 sh
$51.4M

Congress trades in ENOV

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ENOV planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ENOV mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
DAVENPORT SMALL CAP FOCUS FUND
$18.8M position · as of 2026-06-30
3.0%
Tarkio Fund
$7.7M position · as of 2026-05-31
3.0%
Paradigm Micro-Cap Fund
$5.2M position · as of 2026-06-30
2.8%
DAVENPORT EQUITY OPPORTUNITIES FUND
$14.3M position · as of 2026-06-30
1.8%
Small Cap Value Fund
$54.2M position · as of 2026-06-30
1.8%
MML VIP American Century Small Company Value Fund
$1.0M position · as of 2026-06-30
1.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Trerotola
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2020
$8.3M
$8.9M
$3.1M
+5%
+33%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $541.7K bought by insiders over 180 days, 136 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

ENOV financials

Revenue growth
+6.7%
XBRL, annual
Net margin
-52.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.3B
four quarters, 2025-07-05 to 2026-07-03
Net margin, TTM
-48.0%
net income over revenue, 2025-07-05 to 2026-07-03
Free cash flow, TTM
$63.7M
operating cash flow minus capex, 2025-07-05 to 2026-07-03
Debt to equity
0.87x
long-term 2026-07-03 plus current 2026-07-03; equity 2026-07-03
Cash flow to debt
0.21x
TTM operating cash flow over long-term 2026-07-03 plus current 2026-07-03
Return on equity
-54.3%
TTM net income over average of 2025-07-04 and 2026-07-03
Return on assets
-25.1%
TTM net income over average of 2025-07-04 and 2026-07-03
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-27.3%
operating income (EBIT proxy) over average of 2025-07-04 and 2026-07-03 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$2.5B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-07-03 plus current 2026-07-03, minus cash 2026-07-03
FCF yield
+5.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$2.2B$2.1B$1.7B$1.6B
Gross profit$1.3B$1.2B$990.8M$869.4M
Operating income-$1.1B-$775.7M-$65.7M-$71.2M
Net income-$1.2B-$825.5M-$33.3M-$13.3M
EPS (diluted)-20.75-14.93-0.61-0.25
Operating cash flow$217.3M$113.5M$135.0M-$55.9M
Cash$36.4M$48.2M$36.2M$24.3M
Long-term debt$1.3B$1.3B$466.2M$40.0M
Buybacks$3.5M$4.8M$0$0
SEC XBRL, fiscal years, as known on 2026-10-28

ENOV Stock Sonar score 6/7 axes

Find similar shapesCompare

ENOV ranks highest on insider conviction (80th percentile) and institutional and government (63rd), and lowest on growth (40th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
41
Inputs
  • Return on equity-54.3% · 37 pct, sector of 183
  • Return on assets-25.1% · 43 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-27.3% · 43 pct, sector of 188
Financial health
46
Inputs
  • Debt to equity0.87x · 22 pct, sector of 159
  • Cash flow to debt0.21x · 70 pct, sector of 150
Growth
40
Inputs
  • Revenue growth, YoY+6.7% · 40 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
80
Inputs
  • Net Form 4 buying (codes P and S), 180d$542K · 87 pct, sector of 140
  • Insider buyers, 180d2 · 74 pct, sector of 142
Institutional and government
63
Inputs
  • Funds adding, latest quarter136 · 71 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$225K · 55 pct, sector of 50
Risk and compliance
60
Inputs
  • Short interest, % of float+20.0% · 3 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+5.8% · 78 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ENOV filings, in plain words

Are Enovis insiders buying or selling ENOV?

In the 180 days to 2026-10-28, Enovis insiders were net buyers, a net $541.7K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Enovis insiders were net buyers of ENOV, a net $541.7K across purchases and sales reported on Form 4 by 2 buyers. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies